<code id='DE50509AD3'></code><style id='DE50509AD3'></style>
    • <acronym id='DE50509AD3'></acronym>
      <center id='DE50509AD3'><center id='DE50509AD3'><tfoot id='DE50509AD3'></tfoot></center><abbr id='DE50509AD3'><dir id='DE50509AD3'><tfoot id='DE50509AD3'></tfoot><noframes id='DE50509AD3'>

    • <optgroup id='DE50509AD3'><strike id='DE50509AD3'><sup id='DE50509AD3'></sup></strike><code id='DE50509AD3'></code></optgroup>
        1. <b id='DE50509AD3'><label id='DE50509AD3'><select id='DE50509AD3'><dt id='DE50509AD3'><span id='DE50509AD3'></span></dt></select></label></b><u id='DE50509AD3'></u>
          <i id='DE50509AD3'><strike id='DE50509AD3'><tt id='DE50509AD3'><pre id='DE50509AD3'></pre></tt></strike></i>

          Home / hotspot / hotspot

          hotspot


          hotspot

          author:explore    Page View:898
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In